INS and insomnia measurement: The prevalence of insomnia in patients with T2DM has been reported over 40% and compared with the general population, the prevalence of insomnia was higher in patients with T2DM (4) As there are reasonable biological mechanisms linking insomnia to the risk of developing T2DM through increasing insulin resistance and appetite, insomnia can be properly treated as a potentially promising approach to reduce T2DM incidence (5).